Construction
Compare Stocks
5 / 10Stock Comparison
LII vs JCI vs HON vs CARR vs EMR
Revenue, margins, valuation, and 5-year total return — side by side.
Construction
Conglomerates
Construction
Industrial - Machinery
LII vs JCI vs HON vs CARR vs EMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Construction | Construction | Conglomerates | Construction | Industrial - Machinery |
| Market Cap | $18.14B | $85.12B | $135.04B | $55.83B | $79.14B |
| Revenue (TTM) | $5.26B | $24.43B | $36.76B | $21.87B | $18.32B |
| Net Income (TTM) | $783M | $3.53B | $4.10B | $1.32B | $2.44B |
| Gross Margin | 33.1% | 36.6% | 36.9% | 24.8% | 52.7% |
| Operating Margin | 19.5% | 13.6% | 14.9% | 8.1% | 19.8% |
| Forward P/E | 21.5x | 28.8x | 20.2x | 23.9x | 21.7x |
| Total Debt | $2.06B | $11.19B | $34.58B | $12.67B | $13.76B |
| Cash & Equiv. | $34M | $379M | $12.49B | $1.55B | $1.54B |
LII vs JCI vs HON vs CARR vs EMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lennox Internationa… (LII) | 100 | 243.8 | +143.8% |
| Johnson Controls In… (JCI) | 100 | 444.2 | +344.2% |
| Honeywell Internati… (HON) | 100 | 146.1 | +46.1% |
| Carrier Global Corp… (CARR) | 100 | 326.5 | +226.5% |
| Emerson Electric Co. (EMR) | 100 | 231.5 | +131.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LII vs JCI vs HON vs CARR vs EMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LII is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 1.12 vs HON's 11.03
- 14.9% margin vs CARR's 6.0%
- 20.1% ROA vs CARR's 3.5%, ROIC 29.8% vs 6.7%
JCI ranks third and is worth considering specifically for long-term compounding.
- 344.1% 10Y total return vs CARR's 491.3%
- +54.6% vs LII's -8.7%
HON carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 15 yrs, beta 0.74, yield 2.2%
- Lower volatility, beta 0.74, current ratio 1.32x
- Beta 0.74, yield 2.2%, current ratio 1.32x
- 7.8% revenue growth vs CARR's -3.3%
CARR lags the leaders in this set but could rank higher in a more targeted comparison.
EMR is the clearest fit if your priority is growth exposure.
- Rev growth 3.0%, EPS growth 17.8%, 3Y rev CAGR 9.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.8% revenue growth vs CARR's -3.3% | |
| Value | Lower P/E (20.2x vs 21.7x) | |
| Quality / Margins | 14.9% margin vs CARR's 6.0% | |
| Stability / Safety | Beta 0.74 vs EMR's 1.57 | |
| Dividends | 2.2% yield, 15-year raise streak, vs EMR's 1.5% | |
| Momentum (1Y) | +54.6% vs LII's -8.7% | |
| Efficiency (ROA) | 20.1% ROA vs CARR's 3.5%, ROIC 29.8% vs 6.7% |
LII vs JCI vs HON vs CARR vs EMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
LII vs JCI vs HON vs CARR vs EMR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LII leads in 2 of 6 categories
EMR leads 1 • JCI leads 1 • HON leads 0 • CARR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
EMR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HON is the larger business by revenue, generating $36.8B annually — 7.0x LII's $5.3B. LII is the more profitable business, keeping 14.9% of every revenue dollar as net income compared to CARR's 6.0%. On growth, JCI holds the edge at +8.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5.3B | $24.4B | $36.8B | $21.9B | $18.3B |
| EBITDAEarnings before interest/tax | $1.1B | $3.9B | $6.5B | $3.1B | $4.7B |
| Net IncomeAfter-tax profit | $783M | $3.5B | $4.1B | $1.3B | $2.4B |
| Free Cash FlowCash after capex | $661M | $1.4B | $4.2B | $1.7B | $3.1B |
| Gross MarginGross profit ÷ Revenue | +33.1% | +36.6% | +36.9% | +24.8% | +52.7% |
| Operating MarginEBIT ÷ Revenue | +19.5% | +13.6% | +14.9% | +8.1% | +19.8% |
| Net MarginNet income ÷ Revenue | +14.9% | +14.5% | +11.2% | +6.0% | +13.3% |
| FCF MarginFCF ÷ Revenue | +12.6% | +5.7% | +11.4% | +7.6% | +17.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.8% | +8.2% | -6.9% | +2.4% | +2.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -0.6% | +38.9% | -41.9% | -40.4% | +28.2% |
Valuation Metrics
LII leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 23.5x trailing earnings, LII trades at a 56% valuation discount to JCI's 53.0x P/E. Adjusting for growth (PEG ratio), LII offers better value at 1.22x vs HON's 15.77x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $18.1B | $85.1B | $135.0B | $55.8B | $79.1B |
| Enterprise ValueMkt cap + debt − cash | $20.2B | $95.9B | $157.1B | $66.9B | $91.4B |
| Trailing P/EPrice ÷ TTM EPS | 23.46x | 53.05x | 28.96x | 39.31x | 34.97x |
| Forward P/EPrice ÷ next-FY EPS est. | 21.46x | 28.76x | 20.24x | 23.95x | 21.70x |
| PEG RatioP/E ÷ EPS growth rate | 1.22x | 2.07x | 15.77x | — | 7.74x |
| EV / EBITDAEnterprise value multiple | 18.00x | 25.98x | 19.75x | 21.63x | 18.09x |
| Price / SalesMarket cap ÷ Revenue | 3.49x | 3.61x | 3.61x | 2.57x | 4.39x |
| Price / BookPrice ÷ Book value/share | 15.73x | 7.04x | 8.87x | 4.01x | 3.94x |
| Price / FCFMarket cap ÷ FCF | 28.40x | 88.21x | 25.04x | 32.90x | 29.67x |
Profitability & Efficiency
LII leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
LII delivers a 72.0% return on equity — every $100 of shareholder capital generates $72 in annual profit, vs $9 for CARR. EMR carries lower financial leverage with a 0.68x debt-to-equity ratio, signaling a more conservative balance sheet compared to HON's 2.24x. On the Piotroski fundamental quality scale (0–9), EMR scores 7/9 vs CARR's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +72.0% | +24.9% | +23.1% | +9.1% | +12.1% |
| ROA (TTM)Return on assets | +20.1% | +9.0% | +5.3% | +3.5% | +5.8% |
| ROICReturn on invested capital | +29.8% | +8.5% | +12.6% | +6.7% | +8.2% |
| ROCEReturn on capital employed | +40.2% | +9.8% | +12.6% | +7.2% | +10.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 6 | 4 | 7 |
| Debt / EquityFinancial leverage | 1.77x | 0.86x | 2.24x | 0.90x | 0.68x |
| Net DebtTotal debt minus cash | $2.0B | $10.8B | $22.1B | $11.1B | $12.2B |
| Cash & Equiv.Liquid assets | $34M | $379M | $12.5B | $1.6B | $1.5B |
| Total DebtShort + long-term debt | $2.1B | $11.2B | $34.6B | $12.7B | $13.8B |
| Interest CoverageEBIT ÷ Interest expense | 20.51x | 18.41x | 3.92x | 5.76x | 6.46x |
Total Returns (Dividends Reinvested)
JCI leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JCI five years ago would be worth $22,283 today (with dividends reinvested), compared to $10,102 for HON. Over the past 12 months, JCI leads with a +54.6% total return vs LII's -8.7%. The 3-year compound annual growth rate (CAGR) favors JCI at 31.7% vs HON's 4.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.7% | +14.4% | +9.4% | +25.8% | +4.4% |
| 1-Year ReturnPast 12 months | -8.7% | +54.6% | +1.5% | -3.9% | +27.7% |
| 3-Year ReturnCumulative with dividends | +89.9% | +128.3% | +14.7% | +62.8% | +76.2% |
| 5-Year ReturnCumulative with dividends | +53.7% | +122.8% | +1.0% | +55.4% | +59.1% |
| 10-Year ReturnCumulative with dividends | +305.3% | +344.1% | +132.4% | +491.3% | +207.0% |
| CAGR (3Y)Annualised 3-year return | +23.8% | +31.7% | +4.7% | +17.6% | +20.8% |
Risk & Volatility
Evenly matched — JCI and HON each lead in 1 of 2 comparable metrics.
Risk & Volatility
HON is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than EMR's 1.57 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JCI currently trades 94.7% from its 52-week high vs LII's 75.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.28x | 0.95x | 0.74x | 1.21x | 1.57x |
| 52-Week HighHighest price in past year | $689.44 | $147.32 | $248.18 | $81.09 | $165.15 |
| 52-Week LowLowest price in past year | $434.06 | $90.35 | $186.76 | $50.24 | $109.53 |
| % of 52W HighCurrent price vs 52-week peak | +75.6% | +94.7% | +85.9% | +82.4% | +85.6% |
| RSI (14)Momentum oscillator 0–100 | 57.8 | 47.5 | 44.2 | 61.7 | 51.4 |
| Avg Volume (50D)Average daily shares traded | 457K | 3.3M | 3.7M | 6.6M | 2.8M |
Analyst Outlook
Evenly matched — HON and EMR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LII as "Hold", JCI as "Buy", HON as "Buy", CARR as "Buy", EMR as "Buy". Consensus price targets imply 14.4% upside for HON (target: $244) vs 1.0% for CARR (target: $68). For income investors, HON offers the higher dividend yield at 2.17% vs LII's 0.95%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $553.45 | $143.14 | $243.83 | $67.50 | $161.31 |
| # AnalystsCovering analysts | 30 | 45 | 28 | 26 | 41 |
| Dividend YieldAnnual dividend ÷ price | +0.9% | +1.1% | +2.2% | +1.4% | +1.5% |
| Dividend StreakConsecutive years of raises | 12 | 5 | 15 | 6 | 37 |
| Dividend / ShareAnnual DPS | $4.93 | $1.49 | $4.63 | $0.91 | $2.10 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.8% | +7.0% | +2.8% | +5.2% | +1.6% |
LII leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). EMR leads in 1 (Income & Cash Flow). 2 tied.
LII vs JCI vs HON vs CARR vs EMR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LII or JCI or HON or CARR or EMR a better buy right now?
For growth investors, Honeywell International Inc.
(HON) is the stronger pick with 7. 8% revenue growth year-over-year, versus -3. 3% for Carrier Global Corporation (CARR). Lennox International Inc. (LII) offers the better valuation at 23. 5x trailing P/E (21. 5x forward), making it the more compelling value choice. Analysts rate Johnson Controls International plc (JCI) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LII or JCI or HON or CARR or EMR?
On trailing P/E, Lennox International Inc.
(LII) is the cheapest at 23. 5x versus Johnson Controls International plc at 53. 0x. On forward P/E, Honeywell International Inc. is actually cheaper at 20. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Lennox International Inc. wins at 1. 12x versus Honeywell International Inc. 's 11. 03x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — LII or JCI or HON or CARR or EMR?
Over the past 5 years, Johnson Controls International plc (JCI) delivered a total return of +122.
8%, compared to +1. 0% for Honeywell International Inc. (HON). Over 10 years, the gap is even starker: CARR returned +491. 3% versus HON's +132. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LII or JCI or HON or CARR or EMR?
By beta (market sensitivity over 5 years), Honeywell International Inc.
(HON) is the lower-risk stock at 0. 74β versus Emerson Electric Co. 's 1. 57β — meaning EMR is approximately 111% more volatile than HON relative to the S&P 500. On balance sheet safety, Emerson Electric Co. (EMR) carries a lower debt/equity ratio of 68% versus 2% for Honeywell International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — LII or JCI or HON or CARR or EMR?
By revenue growth (latest reported year), Honeywell International Inc.
(HON) is pulling ahead at 7. 8% versus -3. 3% for Carrier Global Corporation (CARR). On earnings-per-share growth, the picture is similar: Emerson Electric Co. grew EPS 17. 8% year-over-year, compared to -72. 4% for Carrier Global Corporation. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LII or JCI or HON or CARR or EMR?
Lennox International Inc.
(LII) is the more profitable company, earning 15. 1% net margin versus 6. 9% for Carrier Global Corporation — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMR leads at 19. 6% versus 9. 9% for CARR. At the gross margin level — before operating expenses — EMR leads at 52. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LII or JCI or HON or CARR or EMR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Lennox International Inc. (LII) is the more undervalued stock at a PEG of 1. 12x versus Honeywell International Inc. 's 11. 03x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Honeywell International Inc. (HON) trades at 20. 2x forward P/E versus 28. 8x for Johnson Controls International plc — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HON: 14. 4% to $243. 83.
08Which pays a better dividend — LII or JCI or HON or CARR or EMR?
All stocks in this comparison pay dividends.
Honeywell International Inc. (HON) offers the highest yield at 2. 2%, versus 0. 9% for Lennox International Inc. (LII).
09Is LII or JCI or HON or CARR or EMR better for a retirement portfolio?
For long-horizon retirement investors, Honeywell International Inc.
(HON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), 2. 2% yield, +132. 4% 10Y return). Emerson Electric Co. (EMR) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HON: +132. 4%, EMR: +207. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LII and JCI and HON and CARR and EMR?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.